African american men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: Should active surveillance still be an option for them?

Journal of Clinical Oncology

Volumn 31, Issue 24, 2013, Pages 2991-2997

  Sundi, Debasish ^a   Ross, Ashley E ^a   Humphreys, Elizabeth B ^a   Han, Misop ^a   Partin, Alan W ^a   Carter, H Ballentine ^a   Schaeffer, Edward M ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE OUTCOME; AFRICAN AMERICAN; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CAUCASIAN; HEALTH DISPARITY; HUMAN; HUMAN TISSUE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; RETROSPECTIVE STUDY; ETHNOLOGY; HEALTH SURVEY; PATHOLOGY; PROSTATE TUMOR; RISK ASSESSMENT; STATISTICS; TREATMENT OUTCOME; UNITED STATES;

AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH STATUS DISPARITIES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 84886860803     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.0302     Document Type: Article

References (28)

1. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Prostate cancer (version 3). http://www.nccn.org/professionals/ physician-gls/pdf/prostate.pdf
2. Conti SL, Dall'era M, Fradet V, et al: Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181:1628-1633, 2009
3. Warlick C, Trock BJ, Landis P, et al: Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98:355-357, 2006 (Pubitemid 43338215)
4. Dall'Era MA, Albertsen PC, Bangma C, et al: Active surveillance for prostate cancer: A systematic review of the literature. Eur Urol 62:976-983, 2012
5. Iremashvili V, Soloway MS, Rosenberg DL, et al: Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. Urology 187:1594-1599, 2012
6. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
7. Resnick MJ, Canter DJ, Guzzo TJ, et al: Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy? Urology 73:620-623, 2009
8. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374, 1994 (Pubitemid 24037911)
9. Epstein JI, Allsbrook WC, Amin MB, et al: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Amer J Surg Pathol 29:1228-1242, 2005 (Pubitemid 41232997)
10. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubicprostatectomy. Cancer 71:3582-3593, 1993 (Pubitemid 23152669)
11. Ross AE, Loeb S, Landis P, et al: Prostatespecific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28:2810- 2816, 2010
12. Cooperberg MR, Hilton JF, Carroll PR: The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117:5039-5046, 2011
13. Amling CL, Riffenburgh RH, Sun L, et al: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22:439-445, 2004 (Pubitemid 41079772)
14. Freedland SJ, Aronson WJ, Kane CJ, et al: Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22:446-453, 2004 (Pubitemid 41079773)
15. Moul JW, Connelly RR, Mooneyhan RM, et al: Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. J Urol 162:394- 397, 1999 (Pubitemid 29434347)
16. Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ: Prostate specific antigen and pathological features of prostate cancer in black and white patients: A comparative study based on radical prostatectomy specimens. J Urol 160:437-442, 1998 (Pubitemid 29476693)
17. Moul JW, Sesterhenn IA, Connelly RR, et al: Prostate-specific antigen values at the time of prostate cancer diagnosis in African American men. JAMA 274:1277-1281, 1995
18. Swords K, Wallen EM, Pruthi RS: The impact of race on prostate cancer detection and choice of treatment in men undergoing a contemporary extended biopsy approach. Urol Oncol 28:280-284, 2010
19. Bigler SA, Pound CR, Zhou X: A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer 2011:239460, 2011
20. Cullen J, Brassell SA, Chen Y, et al: Racial/ ethnic patterns in prostate cancer outcomes in an active surveillance cohort. Prostate Cancer 2011: 234519, 2011
21. Nielsen ME, Han M, Mangold L, et al: Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urology 176:515- 519, 2006 (Pubitemid 43927881)
22. Yamoah K, Stone N, Stock R: Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer 117:5589-5600, 2011
23. Hamilton RJ, Aronson WJ, Presti JC Jr, et al: Race, biochemical disease recurrence, and prostatespecific antigen doubling time after radical prostatectomy: Results from the SEARCH database. Cancer 110:2202-2209, 2007 (Pubitemid 350100741)
24. Moreira DM, Presti JC Jr, Aronson WJ, et al: The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer Prostatic Dis 13:87-93, 2010
25. Ritch CR, Morrison BF, Hruby G, et al: Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro- Caribbean (Jamaican) and Caucasian-American men: An international comparison. BJU Int 111:E186- E190, 2013 (suppl 4 Pt B)
26. Chornokur G, Dalton K, Borysova ME, et al: Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 71:985-997, 2011
27. Powell IJ, Bock CH, Ruterbusch JJ, et al: Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 183:1792-1796, 2010
28. Epstein JI, Carmichael M, Partin AW, et al: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 149: 1478-1481, 1993 (Pubitemid 23164549)